2026 · 2nd Quarter (Apr 1 - June 30)
Filed by CAPITOL COUNSEL LLC.
Open official filingSource-reported fields
Literal source text
Medicare Part B coverage and reimbursement issues for biotechnology treatments and issues related to the Medicare Part D coverage, including issues found in H.R. 1, the One Big Beautiful Bill Act (OBBB) P.L. 119-21
Literal federal measure citations: H.R. 1
Legislative and regulatory issues affecting innovation, including vaccines.
Issues related to tariffs.
Items related to USDA, FDA, genetic engineering, and regulations associated with biotechnology in the Agriculture/Rural Development/Food and Drug Administration proposed Appropriation measures for FY 2027 (House/Senate).
Public health issues impacting patient access to treatments. Updates and reforms to regulation of treatment development and research.
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
